NYSE$SDEV
NovaBay Pharmaceuticals Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
SDEV reported Q3 2025, revenue of $521K, a net loss of $1.3M.
For Q3 2025, SDEV reported revenue of $521K, a net loss of $1.3M. Management discusses operating trends, liquidity, and strategic priorities as disclosed in the quarterly filing.
- Revenue $521K.
- Net loss $1.3M.
- SDEV updated clinical, capital, or portfolio priorities in the filing.
Headline financials
Revenue & EPS history
NovaBay · Revenue · Quarterly
$521K
Forward guidance
Management discusses SDEV's outlook, capital deployment, and key risks as disclosed in the earnings materials and periodic report.
Tailwinds
- SDEV cited progress on strategic priorities in the quarterly filing.
- Liquidity and balance sheet support continued operations and investment.
Headwinds
- GAAP profitability remained under pressure in the reported quarter.
- Macro, competitive, and regulatory factors may affect near-term results.
- R&D, credit, or project timing can create quarter-to-quarter volatility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-0.9%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-6.5%
Avg return
30 days after
37%
24 / 65 earnings
Positive
+74.0%
Q2 2016
Best reaction
-51.1%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | — | — | |
| Q4 2026 | +8.7% | +8.7% | -6.5% | |
| Q3 2025 | +0.0% | +3.8% | +46.2% | |
| Q2 2025 | +3.3% | +71.7% | +331.7% | |
| Q1 2025 | -1.8% | -3.5% | +7.0% | |
| Q3 2024 | -2.9% | +8.3% | -19.4% | |
| Q2 2024 | +11.6% | +0.9% | -81.6% | |
| Q1 2024 | -9.9% | -11.1% | -14.0% | |
| Q4 2023 | -13.7% | -23.1% | -38.5% | |
| Q3 2023 | -2.9% | +0.0% | -12.1% | |
| Q2 2023 | -1.5% | -11.6% | -10.1% | |
| Q1 2023 | -0.8% | -26.5% | -30.6% | |
| Q4 2022 | +3.0% | +3.0% | -30.3% | |
| Q3 2022 | -3.4% | -34.0% | -44.4% | |
| Q2 2022 | -10.0% | -16.1% | -41.9% | |
| Q1 2022 | +4.9% | +11.1% | +22.2% | |
| Q4 2021 | -3.0% | -6.3% | -25.0% | |
| Q3 2021 | -7.6% | -7.1% | -1.8% | |
| Q2 2021 | +0.4% | -7.9% | +0.0% | |
| Q1 2021 | -5.6% | -5.3% | -5.3% | |
| Q4 2020 | -9.2% | -12.9% | -20.8% | |
| Q3 2020 | -1.3% | -6.5% | +11.3% | |
| Q2 2020 | -16.2% | -24.3% | -42.6% | |
| Q1 2020 | -8.9% | -11.6% | -25.0% | |
| Q4 2019 | -13.3% | -31.8% | +2.3% | |
| Q3 2019 | -11.6% | -15.9% | -15.9% | |
| Q2 2019 | -2.5% | -26.3% | -55.9% | |
| Q1 2019 | -51.1% | -15.1% | -62.8% | |
| Q4 2018 | -4.2% | -22.4% | -20.8% | |
| Q3 2018 | +7.2% | +6.4% | +13.6% | |
| Q2 2018 | -10.2% | -9.9% | -40.3% | |
| Q1 2018 | +4.3% | +1.4% | -4.4% | |
| Q4 2017 | +2.9% | +5.7% | -4.3% | |
| Q3 2017 | +4.4% | +9.5% | -18.6% | |
| Q2 2017 | +2.4% | +8.2% | +3.5% | |
| Q1 2017 | -6.7% | -12.3% | -14.1% | |
| Q4 2016 | -0.9% | +1.6% | -13.0% | |
| Q3 2016 | -12.6% | -10.4% | -13.6% | |
| Q2 2016 | +74.0% | +63.9% | +27.7% | |
| Q1 2016 | +5.7% | — | — | |
| Q4 2015 | +7.1% | — | — | |
| Q3 2015 | -7.3% | — | — | |
| Q2 2015 | -4.0% | — | — | |
| Q1 2015 | +11.2% | — | — | |
| Q4 2014 | -5.6% | — | — | |
| Q3 2014 | -0.0% | — | — | |
| Q2 2014 | +5.1% | — | — | |
| Q1 2014 | -4.4% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q2 2013 | +2.1% | — | — | |
| Q1 2013 | +6.3% | — | — | |
| Q4 2012 | +2.4% | — | — | |
| Q3 2012 | -2.3% | — | — | |
| Q2 2012 | -2.5% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | -4.2% | — | — | |
| Q4 2009 | -4.2% | — | — | |
| Q3 2011 | -9.1% | — | — | |
| Q4 2010 | +11.4% | — | — | |
| Q2 2011 | +11.4% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q3 2010 | -0.2% | — | — | |
| Q2 2010 | -0.5% | — | — | |
| Q1 2010 | +4.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro